Isothermal Nucleic Acid Amplification Technology Market to Reach USD 16.7 Billion by 2034
核心洞察
The global isothermal nucleic acid amplification technology (INAAT) market is projected to grow from US$ 5.2 billion in 2024 to US$ 16.7 billion by 2034, at a CAGR of 12.4%.
Loop-mediated isothermal amplification (LAMP) (搜索) leads the technology segment with a 46.4% share, while infectious disease diagnostics dominate applications at 56.7%.
WHO data show 54% (4.5 million) of the 8.3 million people newly diagnosed with tuberculosis (搜索) in 2024 were initially tested using WHO-recommended rapid diagnostic tests.
The global isothermal nucleic acid amplification technology (INAAT) market is expected to grow from US$ 5.2 billion in 2024 to approximately US$ 16.7 billion by 2034, expanding at a compound annual growth rate (CAGR) of 12.4% during the forecast period from 2025 to 2034, according to market analysis published by Market.us. North America held a dominant market position, capturing more than a 43.5% share and holding a US$ 2.3 billion market value for the year.
The growth reflects increasing demand for rapid, accurate, and decentralized diagnostic solutions. Unlike traditional PCR testing, INAAT enables nucleic acid amplification at a constant temperature, reducing the need for complex thermal cycling equipment and making diagnostics more affordable and accessible. This technology is gaining importance in point-of-care (POC), clinical laboratories, and home-based testing applications, especially for infectious disease detection.
Rising Infectious Disease Burden Drives Adoption
The rising burden of infectious diseases is accelerating adoption of INAAT-based solutions. According to the World Health Organization (WHO) (搜索), lower respiratory infections caused more than 2.5 million deaths globally in 2021, highlighting the urgent need for faster disease identification and outbreak response. Advanced INAAT methods, including Loop-Mediated Isothermal Amplification (LAMP) (搜索) and Recombinase Polymerase Amplification (RPA), are improving detection speed, sensitivity, and reliability.
Tuberculosis (搜索) represents a particularly significant application area. WHO's 2025 Global Tuberculosis Report confirms that 8.3 million people were newly diagnosed with TB in 2024, of whom 4.5 million were initially tested with a WHO-recommended rapid diagnostic (WRD), which includes low-complexity nucleic acid amplification tests (NAATs). This corresponds to 54% global coverage, up from 48% in 2023 (8.2 million cases) and 47% in 2022. Isothermal technologies such as TB-LAMP are included among WHO-recommended molecular diagnostic technologies.
Market Segmentation and Technology Landscape
By product type, the market is segmented into reagents and instruments, with the reagents segment dominating in 2023, accounting for a market share of 58.3%. By technology, the market is categorized into LAMP, HDA, NASBA, NEAR, SDA, SPIA, and other technologies, with LAMP technology leading the segment with a significant share of 46.4%.
Based on application, infectious disease diagnostics emerged as the leading segment, capturing the highest revenue share of 56.7%. By end use, hospitals held the dominant position with a revenue share of 51.9%, reflecting their requirement for rapid and accurate diagnostic tools for patient care.
Regulatory Milestones and Decentralized Testing
Technological innovation is expanding market opportunities through portable and battery-operated diagnostic platforms. In February 2023, the U.S. Food and Drug Administration (FDA) (搜索) authorized the first over-the-counter molecular diagnostic test capable of detecting influenza A (搜索), influenza B (搜索), and SARS-CoV-2 (搜索), demonstrating the growing role of decentralized molecular testing. The test delivers results in around 30 minutes using nasal samples.
The Centers for Disease Control and Prevention (CDC) (搜索) reports that rapid molecular influenza assays can provide results within approximately 15–30 minutes, helping clinicians make quicker treatment decisions and improving infectious disease response.
Regional Outlook and Emerging Trends
North America led the market by securing a market share of 43.5% in 2023, supported by advanced healthcare infrastructure, a strong molecular diagnostics ecosystem, and high adoption of rapid testing technologies. The region benefits from significant infectious disease surveillance programs and regulatory support from organizations such as the CDC and FDA.
Asia Pacific is expected to witness notable growth due to increasing healthcare investments, rising infectious disease prevalence, and expanding access to decentralized diagnostic services. According to WHO, countries in the region continue to face significant challenges from diseases such as tuberculosis (搜索) and other infectious conditions, increasing demand for rapid, affordable, and point-of-care molecular testing technologies.
Emerging trends include the growth of portable point-of-care molecular diagnostics, expansion of at-home molecular testing solutions, increasing adoption of multiplex INAAT platforms capable of detecting multiple pathogens from a single sample, and integration of digital health with molecular diagnostics for faster reporting, disease tracking, and surveillance.